GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abliva AB (OTCPK:NEVPF) » Definitions » Common Stock

NEVPF (Abliva AB) Common Stock : $7.34 Mil (As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Abliva AB Common Stock?

Abliva AB's quarterly common stock increased from Jun. 2024 ($6.43 Mil) to Sep. 2024 ($7.88 Mil) but then declined from Sep. 2024 ($7.88 Mil) to Dec. 2024 ($7.34 Mil).

Abliva AB's annual common stock increased from Dec. 2022 ($5.09 Mil) to Dec. 2023 ($5.15 Mil) and increased from Dec. 2023 ($5.15 Mil) to Dec. 2024 ($7.34 Mil).

Abliva AB Common Stock Historical Data

The historical data trend for Abliva AB's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abliva AB Common Stock Chart

Abliva AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.77 2.22 5.09 5.15 7.34

Abliva AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.15 5.07 6.43 7.88 7.34

Abliva AB Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Abliva AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abliva AB (OTCPK:NEVPF) » Definitions » Common Stock
Comparable Companies
OSTO:MAGLE OSTO:IRLAB A XSAT:HAMLET B OSTO:ATORX OSTO:SANION OSTO:FLUO OSTO:SYNACT OSTO:IBT B OSTO:INIT OSTO:IMMU VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
ABLI:Sweden NTP:Germany
Address
Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Website
https://www.abliva.com
Abliva AB is a Swedish company that is active in pharmaceutical development. It develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell's energy provider, the mitochondria, does not function properly. The portfolio includes projects at different stages and ranges from the early discovery phase to the clinical phase. . The company is focused on two projects. KL1333, a powerful NAD+ and NADH regulator, in late-stage development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement therapy, has just completed preclinical development.